For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Group 1: Micron Technology, Inc. (MU) - Micron Technology has a Zacks Rank of 1 and a PEG ratio of 0.33, significantly lower than the industry average of 1.26 [1] - The Zacks Consensus Estimate for Micron's current year earnings has increased by 22.4% over the last 60 days [1] - The company possesses a Growth Score of A, indicating strong growth characteristics [1] Group 2: Sanmina Corporation (SANM) - Sanmina Corporation also holds a Zacks Rank of 1 and has a PEG ratio of 0.61, compared to the industry average of 1.75 [2] - The Zacks Consensus Estimate for Sanmina's current year earnings has risen by 38.9% over the last 60 days [2] - The company has a Growth Score of A, reflecting its strong growth potential [2] Group 3: Phibro Animal Health Corporation (PAHC) - Phibro Animal Health Corporation carries a Zacks Rank of 1 and has a PEG ratio of 1.14, which is lower than the industry average of 1.65 [3] - The Zacks Consensus Estimate for Phibro's current year earnings has increased by 9.1% over the last 60 days [3] - The company possesses a Growth Score of B, indicating solid growth characteristics [3]

Core Insights - Phibro Animal Health (PAHC) shares have increased by 59.6% this year, significantly outperforming the industry and the S&P 500 [1][2] Company Performance - The company holds a Zacks Rank 1 (Strong Buy) and is benefiting from the strong performance of its Animal Health portfolio, particularly in vaccines and emerging markets [2][4] - Phibro markets around 800 product lines across approximately 90 countries, focusing on food and companion animals, and is expanding its product offerings in the companion animal sector [3][4] Revenue Growth - The surge in share price is attributed to strong traction in the Animal Health business, with medicated feed additives (MFA) revenues growing by 81% in Q1 of fiscal 2026, bolstered by the integration of Zoetis' MFA business [4][9] - Vaccine sales increased by 25% year over year in Q1 of fiscal 2026, with management identifying vaccines as a key growth driver [5][9] Global Expansion - Phibro's sales in Europe, the Middle East, and Africa rose by 44.4%, while Asia Pacific sales surged by 101.1% in Q1 of fiscal 2026, reflecting the company's successful global expansion strategy [6][9] Financial Estimates - The Zacks Consensus Estimate predicts a 32.1% increase in earnings per share (EPS) for fiscal 2026, reaching $2.76, and a 6.2% increase for fiscal 2027, reaching $2.93 [11] - Revenues for fiscal 2026 are projected to grow by 13.1% to $1.47 billion, with fiscal 2027 revenues expected to reach $1.51 billion, indicating a 2.8% increase [11]

Core Insights - The U.S. equity markets experienced significant volatility recently, with a five-day winning streak interrupted by a decline in cryptocurrencies, particularly Bitcoin, which struggled to maintain a value above $90,000 [1][2] - Concerns regarding the high valuations of AI firms are prevalent, with expectations of a market correction due to growth not matching substantial investments [2] - The likelihood of the Federal Reserve reducing its benchmark borrowing rate has increased, with markets pricing in an approximately 89% chance of a rate cut at the upcoming meeting [2] Momentum Investing Strategy - Momentum investing is characterized by the strategy of "buying high and selling higher," capitalizing on established trends in stock prices [3] - This investment approach is based on the human tendency to project current trends into the future, allowing investors to profit before prices revert to their mean [3][4] - Momentum strategies have historically generated alpha across various market conditions, although identifying trends can be challenging [4] Screening Parameters for Momentum Stocks - The screening process identifies the top 50 stocks with the highest percentage price change over the past 52 weeks, ensuring selection of stocks with consistent appreciation [5] - From these, the 10 worst performers over the past week are chosen to identify those experiencing short-term pullbacks [6] - Stocks are further filtered by Zacks Rank 1 (Strong Buy) and a Momentum Style Score of B or better, indicating strong potential for success [7] Selected Momentum Stocks - Phibro Animal Health Corporation (PAHC) has seen a 74.9% increase over the past year but a recent decline of 8.2%, holding a Momentum Score of B [11] - Argan, Inc. (AGX) has surged 138.5% in the past year with a recent drop of 4.2%, achieving a Momentum Score of A [13] - Ubiquiti Inc. (UI) has increased by 56.6% over the past year but lost 2% in the last week, also holding a Momentum Score of A [15]

Core Insights - Three stocks with strong momentum and buy rankings are highlighted for investors: Phibro Animal Health, Seanergy Maritime Holdings, and California BanCorp Company Summaries - **Phibro Animal Health (PAHC)**: A leading global diversified animal health and mineral nutrition company, providing a wide range of products for food animals. The Zacks Consensus Estimate for its current year earnings increased by 7.4% over the last 60 days. The stock gained 33.3% over the last three months, outperforming the S&P 500's gain of 3.8%. The company has a Momentum Score of A [1][2]. - **Seanergy Maritime Holdings (SHIP)**: A prominent pure-play Capesize ship-owner providing marine dry bulk transportation services through a modern fleet. The Zacks Consensus Estimate for its current year earnings increased by 66.7% over the last 60 days. The stock gained 25.9% over the last three months, also outperforming the S&P 500's gain of 3.8%. The company has a Momentum Score of A [2][3]. - **California BanCorp (BCAL)**: A registered bank holding company offering a range of financial products and services to individuals and small to medium-sized businesses. The Zacks Consensus Estimate for its current year earnings increased by 6.3% over the last 60 days. The stock gained 12.7% over the last three months, again outperforming the S&P 500's gain of 3.8%. The company has a Momentum Score of B [3][4].

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are highlighted, indicating a looming crisis in power supply as AI continues to grow [2][3] Investment Opportunity - A specific company is presented as a significant investment opportunity, positioned to benefit from the increasing energy demands of AI data centers [3][6] - This company is not a chipmaker or cloud platform but owns critical energy infrastructure assets essential for supporting the AI energy spike [3][7] Energy Infrastructure - The company is described as a "Toll Booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend driven by tariffs [5][6] - It possesses critical nuclear energy infrastructure, making it integral to America's future power strategy [7][8] Financial Position - The company is noted for being debt-free and holding a significant cash reserve, equating to nearly one-third of its market capitalization [8][10] - It is trading at less than 7 times earnings, indicating a potentially undervalued position in the market [10][12] Market Trends - The article discusses the broader trends of AI, energy, tariffs, and onshoring, suggesting that this company is well-positioned to capitalize on these developments [6][14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, further solidifying the importance of investing in AI-related companies [12][13] Conclusion - The narrative emphasizes the urgency for investors to engage in the AI sector, particularly through this company, which is poised for significant growth amid the ongoing technological revolution [15][19]

Core Insights - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article suggests that users may face blocks if ad-blockers are enabled, indicating a need to disable them for proper access [1]

Group 1 - The article does not provide any specific information or insights regarding a company or industry [1]

Financial Performance and Key Metrics - Consolidated net sales for Q1 2026 were $363.9 million, a 40% increase year-over-year, driven by a 55% growth in the animal health segment [8][9] - Adjusted EBITDA for Q1 increased by 102% to $31.2 million, with adjusted net income rising by 112% and adjusted diluted EPS increasing by 108% [8][9] - The animal health segment's net sales reached $283.5 million, reflecting a 55% increase, while mineral nutrition grew by 7% and performance products declined by 7% [9][10] Business Line Performance - Medicated feed additives saw an 81% growth, with the new MFA business contributing $80.5 million in sales [5][9] - Nutritional specialties net sales increased by 13%, primarily due to higher demand for microbial and companion animal products [9] - Vaccine sales grew by 25%, driven by poultry products in Latin America and increased international demand [9] Market Data and Key Metrics - Strong demand for animal-based proteins is noted, supported by global population growth and changing consumer preferences towards high-quality proteins [30] - Livestock sector profitability remains positive across various regions, with lower feed costs encouraging investment in animal health products [30][31] Company Strategy and Industry Competition - The company is focused on innovation and execution, with the recent launch of Restoris, a dental gel for dogs, marking a significant step in the companion animal strategy [6][23] - The Phibro-forward initiatives aim to enhance operational discipline and drive sustainable long-term value creation [6][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for products globally and anticipates continued improvement in business performance [13][14] - The company raised its full-year earnings guidance, reflecting strong performance and disciplined financial management [12][13] Other Important Information - The company generated $34 million in positive free cash flow for the 12 months ending September 30, 2025, with a gross leverage ratio of 3.3 times [11] - A quarterly dividend of $0.12 per share was paid, totaling $4.9 million [12] Q&A Session Summary Question: Sustainability of growth in the MFA business - Management noted strong demand across the MFA portfolio, particularly in poultry, swine, and beef cattle segments, with limited impact on pricing in Q1 [15][16][17] Question: Margin profile for the remainder of the year - Management indicated that Q1 margins were favorable due to product mix, but expected a slight drop in margins as investments in new product launches occur [18][19] Question: Guidance update and revenue range - Management explained that while EBITDA and EPS guidance were raised, revenue guidance remained unchanged due to conservatism and being only one quarter into the fiscal year [21][22] Question: Role in the companion animal market - Management confirmed a focus on unique opportunities in the companion animal space, rather than competing directly with larger players [34][36]